ProfileGDS5678 / 1423141_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 85% 85% 85% 87% 84% 79% 86% 82% 83% 84% 85% 82% 85% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.2783985
GSM967853U87-EV human glioblastoma xenograft - Control 26.4680785
GSM967854U87-EV human glioblastoma xenograft - Control 36.3192685
GSM967855U87-EV human glioblastoma xenograft - Control 46.9145287
GSM967856U87-EV human glioblastoma xenograft - Control 56.2258284
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4030579
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.4230886
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8878782
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.0356783
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.2530484
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3130885
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0521882
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.295185
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.1662784